Strategic Financial Concepts LLC Makes New $8.88 Million Investment in Becton, Dickinson and Company (NYSE:BDX)

Strategic Financial Concepts LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, HoldingsChannel reports. The fund bought 39,148 shares of the medical instruments supplier’s stock, valued at approximately $8,882,000.

A number of other hedge funds also recently made changes to their positions in BDX. Good Life Advisors LLC boosted its stake in Becton, Dickinson and Company by 20.9% in the third quarter. Good Life Advisors LLC now owns 1,145 shares of the medical instruments supplier’s stock valued at $276,000 after acquiring an additional 198 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Becton, Dickinson and Company by 2.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 33,045 shares of the medical instruments supplier’s stock valued at $7,967,000 after purchasing an additional 633 shares during the last quarter. Stonegate Investment Group LLC grew its holdings in Becton, Dickinson and Company by 5.0% during the third quarter. Stonegate Investment Group LLC now owns 5,536 shares of the medical instruments supplier’s stock valued at $1,335,000 after purchasing an additional 264 shares during the period. Aspiriant LLC raised its stake in shares of Becton, Dickinson and Company by 8.4% in the third quarter. Aspiriant LLC now owns 1,171 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 91 shares during the period. Finally, Stratos Wealth Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 9.8% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 3,274 shares of the medical instruments supplier’s stock valued at $790,000 after buying an additional 291 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BDX. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Barclays boosted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Trading Down 0.1 %

Becton, Dickinson and Company stock opened at $224.89 on Friday. The stock has a market cap of $65.22 billion, a P/E ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.40. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The firm’s fifty day moving average price is $232.60 and its 200-day moving average price is $233.73. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.85%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.